Curis Inc (CRIS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Curis Inc stock (CRIS) is currently trading at $0.71. Curis Inc PS ratio (Price-to-Sales) is 0.91. Analyst consensus price target for CRIS is $14.00. WallStSmart rates CRIS as Sell.
- CRIS PE ratio analysis and historical PE chart
- CRIS PS ratio (Price-to-Sales) history and trend
- CRIS intrinsic value — DCF, Graham Number, EPV models
- CRIS stock price prediction 2025 2026 2027 2028 2029 2030
- CRIS fair value vs current price
- CRIS insider transactions and insider buying
- Is CRIS undervalued or overvalued?
- Curis Inc financial analysis — revenue, earnings, cash flow
- CRIS Piotroski F-Score and Altman Z-Score
- CRIS analyst price target and Smart Rating
Curis Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Curis Inc (CRIS) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Curis Inc (CRIS) Key Strengths (1)
Paying less than $1 for every $1 of annual revenue
Supporting Valuation Data
Curis Inc (CRIS) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 4.3x book value
Modest revenue growth at 8.40%
Moderate institutional interest at 31.55%
Curis Inc (CRIS) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales. Valuation metrics including Price/Sales (0.91) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Market Cap. Some valuation metrics including Price/Book (4.32) suggest expensive pricing. Growth concerns include Revenue Growth at 8.40%, which may limit upside. Profitability pressure is visible in Return on Equity at -2951.00%, Operating Margin at -218.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -2951.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 8.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CRIS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CRIS's Price-to-Sales ratio of 0.91x trades at a deep discount to its historical average of 2.71x (6th percentile). The current valuation is 86% below its historical high of 6.43x set in Jan 2006, and 52% above its historical low of 0.6x in Nov 2008. Over the past 12 months, the PS ratio has compressed from ~1.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Curis Inc (CRIS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Curis Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 12M with 8% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of -2.08 indicates a conservative balance sheet with 9M in cash.
Spending 50% of revenue (6M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.98, so expect amplified moves relative to the broader market.
Debt management: total debt of 31M is significantly higher than cash (9M). Monitor refinancing risk.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Curis Inc.
Bottom Line
Curis Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Curis Inc(CRIS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. The company is headquartered in Lexington, Massachusetts.